Soc. Generale Knock-Out GNMSF/ DE000CL7HDE8 /
5/31/2024 12:05:19 PM | Chg.-0.030 | Bid12:46:22 PM | Ask12:46:22 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
3.850EUR | -0.77% | 3.870 Bid Size: 4,000 |
3.910 Ask Size: 4,000 |
Genmab A/S | 1,657.03 - | 12/31/2078 | Call |
GlobeNewswire
4/30
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
4/3
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
10/17/2023
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
9/25/2023
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
9/4/2023
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
10/19/2021
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
GlobeNewswire
9/20/2021
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previous...
GlobeNewswire
7/21/2021
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021